Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
CRBP Quote, Financials, Valuation and Earnings
Last price:
$7.40
Seasonality move
:
41.37%
Day range:
$7.23 - $7.67
52-week range:
$4.64 - $20.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
70.76x
P/B ratio:
1.41x
Volume:
101.7K
Avg. volume:
157.6K
1-year change:
-10.39%
Market cap:
$130.2M
Revenue:
--
EPS (TTM):
-$5.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
$1.1M | -$1.60 | -- | -103.83% | $42.33 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
$7.42 | $42.33 | $130.2M | -- | $0.00 | 0% | 70.76x |
|
AGEN
Agenus, Inc.
|
$3.06 | $12.33 | $110.6M | -- | $0.00 | 0% | 0.77x |
|
CRIS
Curis, Inc.
|
$1.11 | $14.00 | $14.4M | -- | $0.00 | 0% | 1.06x |
|
LADX
LadRx Corp.
|
$0.0014 | -- | $700 | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0120 | $4.0000 | $404.5K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
2.18% | 2.834 | 1.29% | 6.11x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
|
-$100K | -$24.4M | -52.96% | -54.17% | -- | -$15.6M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Corbus Pharmaceuticals Holdings, Inc. vs. Competitors
-
Which has Higher Returns CRBP or AGEN?
Agenus, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -116.82%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 470.53%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 303.05%. Given that Corbus Pharmaceuticals Holdings, Inc. has higher upside potential than Agenus, Inc., analysts believe Corbus Pharmaceuticals Holdings, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 AGENAgenus, Inc.2 1 0 -
Is CRBP or AGEN More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.865, which suggesting that the stock is 186.504% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or AGEN?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 0.77x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M AGENAgenus, Inc.0.77x -- $30.2M $63.9M
-
Which has Higher Returns CRBP or CRIS?
Curis, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -243.36%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 470.53%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1161.26%. Given that Curis, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Curis, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 CRISCuris, Inc.4 0 0 -
Is CRBP or CRIS More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.865, which suggesting that the stock is 186.504% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or CRIS?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 1.06x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M CRISCuris, Inc.1.06x -- $3.2M -$7.7M
-
Which has Higher Returns CRBP or LADX?
LadRx Corp. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of --. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About CRBP or LADX?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 470.53%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 32142757.14%. Given that LadRx Corp. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe LadRx Corp. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 LADXLadRx Corp.0 0 0 -
Is CRBP or LADX More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.865, which suggesting that the stock is 186.504% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock CRBP or LADX?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or LADX?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns CRBP or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of -316.61%. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About CRBP or PSTV?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 470.53%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is CRBP or PSTV More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.865, which suggesting that the stock is 186.504% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock CRBP or PSTV?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRBP or PSTV?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
-
Which has Higher Returns CRBP or WINT?
Windtree Therapeutics, Inc. has a net margin of -- compared to Corbus Pharmaceuticals Holdings, Inc.'s net margin of --. Corbus Pharmaceuticals Holdings, Inc.'s return on equity of -54.17% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital CRBPCorbus Pharmaceuticals Holdings, Inc.-- -$1.90 $94.2M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About CRBP or WINT?
Corbus Pharmaceuticals Holdings, Inc. has a consensus price target of $42.33, signalling upside risk potential of 470.53%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 33233.33%. Given that Windtree Therapeutics, Inc. has higher upside potential than Corbus Pharmaceuticals Holdings, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Corbus Pharmaceuticals Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRBPCorbus Pharmaceuticals Holdings, Inc.8 0 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is CRBP or WINT More Risky?
Corbus Pharmaceuticals Holdings, Inc. has a beta of 2.865, which suggesting that the stock is 186.504% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
-
Which is a Better Dividend Stock CRBP or WINT?
Corbus Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corbus Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRBP or WINT?
Corbus Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Windtree Therapeutics, Inc. quarterly revenues of --. Corbus Pharmaceuticals Holdings, Inc.'s net income of -$23.3M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Corbus Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corbus Pharmaceuticals Holdings, Inc. is 70.76x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRBPCorbus Pharmaceuticals Holdings, Inc.70.76x -- -- -$23.3M WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
